公开(公告)号：US11793875B2

公开(公告)日：2023-10-24

申请号：US17745937

申请日：2022-05-17

Applicant: Austin Research Labs Corp.

Inventor： Jai Supamahitorn ,  Lauren McMillan

IPC: A61K47/02 ,  A61K47/52 ,  A01N25/04 ,  A01N39/00 ,  A01N33/12 ,  A61K9/10 ,  A61K31/14 ,  A61K45/06 ,  A61K31/167

CPC classification number: A61K47/02 ,  A01N25/04 ,  A01N33/12 ,  A01N39/00 ,  A61K9/10 ,  A61K31/14 ,  A61K31/167 ,  A61K45/06 ,  A61K47/52 ,  Y02A50/30 ,  A01N25/04 ,  A01N33/12 ,  A01N39/00 ,  A01N39/00 ,  A01N25/08 ,  A01N37/18 ,  A01N2300/00

Abstract: The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds.

公开(公告)号：US20230248701A1

公开(公告)日：2023-08-10

申请号：US18167059

申请日：2023-02-09

Applicant: Somerset Therapeutics, LLC

Inventor： Mandar V. Shah ,  Ilango Subramanian ,  Veerappan Subramanian ,  Aman Trehan

IPC: A61K31/4178 ,  A61K31/498 ,  A61K47/44 ,  A61K47/26 ,  A61K31/14 ,  A61K9/00

CPC classification number: A61K31/4178 ,  A61K31/498 ,  A61K47/44 ,  A61K47/26 ,  A61K31/14 ,  A61K9/0048

Abstract: The present invention provides, stable, pharmaceutically acceptable and ophthalmologically suitable gel compositions comprising therapeutically effective amounts of both a pilocarpine compound and a brimonidine compound and effective amount(s) of at least one polyethoxylated castor oil, which in aspects is/are present in a defined ratio with one or more active pharmaceutical ingredients. In aspects, such compositions are formulated as gel compositions. In certain embodiments, provided compositions are free of both a borate buffer and a citrate buffer. Compositions provided by the invention demonstrate stability, e.g., pH and active pharmaceutical ingredient stability, when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions and methods of their use in treating ocular conditions, such as presbyopia.

公开(公告)号：US20230248700A1

公开(公告)日：2023-08-10

申请号：US18167057

申请日：2023-02-09

Applicant: Somerset Therapeutics, LLC

Inventor： Mandar V. Shah ,  Ilango Subramanian ,  Veerappan Subramanian ,  Aman Trehan

IPC: A61K31/4178 ,  A61K31/498 ,  A61K9/00 ,  A61K47/02 ,  A61K31/14

CPC classification number: A61K31/4178 ,  A61K31/498 ,  A61K9/0048 ,  A61K47/02 ,  A61K31/14

Abstract: The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions in liquid (solution) and gel forms, and methods of their use in treating conditions such as presbyopia.

公开(公告)号：US20230233467A1

公开(公告)日：2023-07-27

申请号：US18159030

申请日：2023-01-24

Applicant: Nutraceutical Corporation

Inventor： Max F. Willis ,  Neil C. Roberts

IPC: A61K9/127 ,  A61K35/60 ,  A61K33/26 ,  A61K31/728 ,  A61K36/81 ,  A61K31/198 ,  A61K36/42 ,  A61K36/45 ,  A61K31/122 ,  A61K31/07 ,  A61K31/375 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/525 ,  A61K31/455 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/14 ,  A61K33/32 ,  A61K33/30 ,  A61K33/24 ,  A61K33/06 ,  A61K33/04 ,  A61K47/24

CPC classification number: A61K9/127 ,  A61K35/60 ,  A61K33/26 ,  A61K31/728 ,  A61K36/81 ,  A61K31/198 ,  A61K36/42 ,  A61K36/45 ,  A61K31/122 ,  A61K31/07 ,  A61K31/375 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/525 ,  A61K31/455 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/14 ,  A61K33/32 ,  A61K33/30 ,  A61K33/24 ,  A61K33/06 ,  A61K33/04 ,  A61K47/24

Abstract: Compositions and methods for increasing absorption of nutrients by a body. A composition includes a liposome comprising a lipid bilayer, wherein the liposome comprises an internal core. The composition includes a nutrient payload disposed within the liposome. The nutrient payload comprises a plurality of different supplement nutrients comprising one or more of a vitamin, mineral, extract, enzyme, or amino acid.

公开(公告)号：US11707465B2

公开(公告)日：2023-07-25

申请号：US17884346

申请日：2022-08-09

Applicant: Ortho-Nutra, LLC

Inventor： Hector L. Lopez ,  Shawn Wells ,  Tim N. Ziegenfuss

IPC: A61K31/522 ,  C07D487/04 ,  A23L33/10 ,  A23L33/105 ,  A61K31/133 ,  A61K31/14 ,  A61K31/4748 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068

CPC classification number: A61K31/522 ,  A23L33/10 ,  A23L33/105 ,  A61K31/133 ,  A61K31/14 ,  A61K31/4748 ,  A61K31/685 ,  A61K31/7048 ,  A61K31/7068 ,  C07D487/04 ,  A23V2002/00

Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

公开(公告)号：US11679096B1

公开(公告)日：2023-06-20

申请号：US17966916

申请日：2022-10-17

Applicant: Matthias W Rath

Inventor： Aleksandra Niedzwiecki ,  Matthias W Rath ,  Anna Goc ,  Gabriela Lopez

IPC: A61K31/375 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/525 ,  A61K33/18 ,  A61K33/04 ,  A61P43/00 ,  A61K31/047 ,  A61K31/685 ,  A61K31/352 ,  A61K36/48 ,  A61K36/53 ,  A61K31/14

CPC classification number: A61K31/355 ,  A61K31/047 ,  A61K31/14 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/525 ,  A61K31/685 ,  A61K33/04 ,  A61K33/18 ,  A61K36/48 ,  A61K36/53 ,  A61P43/00

Abstract: The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).

公开(公告)号：US20230181608A1

公开(公告)日：2023-06-15

申请号：US18078165

申请日：2022-12-09

Applicant: Heilongjiang Feihe Dairy Co., Ltd.

Inventor： Qinggang XIE ,  Dongying CUI ,  Shilong JIANG ,  Aimei LIANG ,  Yongjiu ZHANG ,  Fangliang CAI ,  Youbin LENG ,  Siyu LU

IPC: A61K31/702 ,  A23L33/00 ,  A23C9/20 ,  A23L33/21 ,  A61K31/14 ,  A61K35/20 ,  A61K9/00 ,  A61P25/28 ,  A61K47/26 ,  A61K47/44

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A23L33/40 ,  A61K9/0095 ,  A61K31/14 ,  A61K35/20 ,  A61K47/26 ,  A61K47/44 ,  A61P25/28 ,  A23V2002/00

Abstract: The invention relates to a nutrient composition, a food including the same and use of the nutrient composition. The nutrition composition includes: human milk oligosaccharide, preferably neutral fucosylated human milk oligosaccharide, which is preferably one or more selected from the group consisting of: 2′-fucosyl lactose, 3′-fucosyl lactose, lacto-N-fucopentaose I, lacto-N-difucohexaose I, lacto-N-difucohexaose II, preferably 2′-fucosyl lactose (2′-FL); milk fat globule membrane; and choline and/or an edible choline derivative. The nutritional composition can improve the brain development and intelligence of babies, infants and young children, especially promote neurodevelopment such as neuron maturation, synaptogenesis and myelination.

公开(公告)号：US11673129B2

公开(公告)日：2023-06-13

申请号：US17066270

申请日：2020-10-08

Applicant: ACENET INC.

Inventor： Kiyoto Takamori ,  Takekatsu Shibata

IPC: B01J31/02 ,  C07D219/06 ,  C07C63/06 ,  C07C51/235 ,  C07F15/06 ,  A61P31/04 ,  A61K31/14 ,  A61K33/20 ,  C07B61/00 ,  C07C29/48 ,  C07F9/53

CPC classification number: B01J31/0239 ,  A61K31/14 ,  A61K33/20 ,  A61P31/04 ,  B01J31/0204 ,  B01J31/0224 ,  B01J31/0271 ,  C07B61/02 ,  C07C29/48 ,  C07C51/235 ,  C07C63/06 ,  C07D219/06 ,  C07F15/06 ,  C07F15/065 ,  B01J2231/70 ,  C07B61/00 ,  C07F9/53

Abstract: An object of a first aspect of the present invention is to provide a radical generating catalyst that can generate (produce) radicals under mild conditions. In order to achieve the above object, a first radical generating catalyst according to the first aspect of the present invention is characterized in that it includes ammonium and/or a salt thereof. A second radical generating catalyst according to the first aspect of the present invention is characterized in that it includes an organic compound having Lewis acidic properties and/or Brønsted acidic properties.

公开(公告)号：US20230098327A1

公开(公告)日：2023-03-30

申请号：US17899150

申请日：2022-08-30

Applicant: Premier Nutrition Company, LLC

Inventor： Madhavi Ummadi ,  Nishtha Lukhmana ,  Venkata Sarath Pamu ,  Liqiang Zhao ,  Kimberly Ann Swisher Lutze ,  Emily Elizabeth Hurt

IPC: A61K35/20 ,  A61K9/00 ,  A61K47/42 ,  A61K47/38 ,  A61K33/30 ,  A61K33/06 ,  A61K31/07 ,  A61K31/122 ,  A61K31/355 ,  A61K31/593 ,  A61K31/4415 ,  A61K31/375 ,  A61K31/519 ,  A61K31/14 ,  A61K47/36 ,  A61K47/24 ,  A61K38/08

Abstract: Described herein is an innovative composition that improves sleep quality. This composition includes two important systems: 1) a sleep-inducing system that is being used for the first time in food and beverage products; and 2) a unique stabilizer system that provides a robust rheology and greater stability than other stabilizers. The two systems can be incorporated, individually or in combination, into food and beverage products, including but not limited to protein shakes and powders. Together, they enable this composition to aid in relaxation and optimal sleep quality, better sensory taste experiences than current market products, longer shelf life and robust stability. This disclosure also addresses a relevant need in the art for a beverage composition that promotes calmness and reduces stress by using natural ingredients, more specifically made from milk casein. In summary, the sleep-inducing RTD (ready-to-drink) and RTM (ready-to-mix) compositions described herein include a stabilizer composition that improves shelf-life stability and contributes to enhanced specific sensory attributes without any adverse effects.

公开(公告)号：US20230074237A1

公开(公告)日：2023-03-09

申请号：US17682051

申请日：2022-02-28

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Perez Barranco ,  Maria Ramirez Gonzalez ,  Rachael BUCK ,  Enrique Vazquez Hernandez

IPC: A61K35/747 ,  A23L33/125 ,  A23L33/15 ,  A23L33/135 ,  A23L33/00 ,  A61P1/14 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.